The US/MX Border Is Always Open For Our Treatments, and is considered Essential Travel. Only A US Passport is required.

Stem Cell Therapy For Lung Disease

After an intravenous infusion of Wharton's jelly-derived umbilical mesenchymal stem cells, the first destination for these stem cells is the lungs. This is what makes them highly effective for the treatment of lung diseases. Stem cell therapy, using Wharton's jelly-derived umbilical MSCs and offered at all our treatment centers in Mexico and Colombia, is an adjunct treatment option to maintain healthier lungs and enhance the lung's ability to regulate immunity, inhibit inflammation, and promote the repair of epithelial tissue.

Stem cell therapy can be used as an adjunct in the treatment of diseases such as:

  • EPOC
  • Pulmonary Fibrosis
  • Acute Lung Injury
  • Asthma
  • Bronchopulmonary Dysplasia
stem cell rejuvenation for lung disease | stem cell therapy | stem cell therapy treatment

The cost of the treatment.

The cost is determined based on the dosage and protocol recommended by the doctor, and this is done through a free virtual medical consultation.

Duration of your visit.

The treatment has an approximate duration of 2 to 3 hours, depending on the medical assessment. Some patients may receive their treatment divided into two or more days.

Ground transportation support.

We provide transportation from the hotel to the clinic. In the clinics located in Nuevo Laredo, Ciudad Juárez, and Ensenada, transportation is offered from your hotel in the United States to the clinic. In the clinics in Monterrey, Guadalajara, Cabo, and Los Algodones, we offer transfers from the airport to your hotel and on the day of treatment to the clinic. In Cancún, transportation is only provided from your hotel to the clinic on the day of treatment.


Akram KM, Samad S, Spiteri M, Forsyth NR. Mesenchymal stem cell therapy and lung diseases. Adv Biochem Eng Biotechnol. 2013;130:105-29. doi: 10.1007/10_2012_140. PMID: 22772131.

Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. Stem Cells Int. 2019 May 2;2019:4236973. doi: 10.1155/2019/4236973. PMID: 31191672; PMCID: PMC6525794.

Wecht S, Rojas M. Mesenchymal stem cells in the treatment of chronic lung disease. Respirology. 2016 Nov;21(8):1366-1375. doi: 10.1111/resp.12911. Epub 2016 Sep 29. PMID: 27688156.

Click Here for your FREE Doctor Consultation or more information

Monday – Saturday
8:30 a.m – 5:30 p.m.
© 2010-2024 Trinity Stem Cells ALL RIGHTS RESERVED
Top chevron-down